Ayşe ÇEÇEN
(Samsun Eğitim ve Araştırma Hastanesi, Kulak Burun Boğaz Anabilim Dalı, Samsun, Türkiye)
Özgür KEMAL
(Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Kulak Burun Boğaz Anabilim Dalı, Samsun, Türkiye)
ÖZLEM TERZİ
(Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Halk Sağlığı Anabilim Dalı, Samsun, Türkiye)
Mustafa TAŞTAN
(Ondokuz Mayıs Üniversitesi Tıp Fakültesi, Kulak Burun Boğaz Anabilim Dalı, Samsun, Türkiye)
Yıl: 2021Cilt: 11Sayı: 2ISSN: 2149-7109 / 2149-6498Sayfa Aralığı: 81 - 86İngilizce

2 0
The Outcomes in Patients Treated With Intratympanic and Systemic Steroids for Sudden Hearing Loss and Prognostic Factors
Objective: Steroid therapy is the gold standard in treating sudden sensorineural hearing loss (SSNHL). This study aimed to compare the results of the systemic and intratympanic administration of steroids used to treat patients with SSNHL. Methods: A retrospective analysis was performed with 90 patients treated for SSNHL in our clinic between 2014 and 2017. Intratympanic steroid (ITS) was administered to 44 patients and systemic administration (intravenous or oral) to 46. Pure-tone average (PTA) values were recorded before treatment and at the first and third months post-treatment. Hearing improvement was evaluated according to the Furahashi criteria. Results: The pre-treatment PTA values were 68.9 ± 25.9 dB in the systemic steroidtreated group and 79.0 ± 22.6 dB in the intratympanic steroid-treated group, with no statistically significant difference determined (P = .07). After 1 month of treatment, the PTA median value was 6.0 (from −23.0 to −65.0) dB in the systemic group; and the median was 7.5 dB (from −13.0 to −84.0) in the intratympanic group. No statistically significant difference was determined between the groups in terms of regression in pure-tone median values after treatment (P = .90). According to the Furahashi criteria, in the evaluations between the 2 groups, those with complete improvement and significant improvement were compared together, and those with mild improvement and those without improvement were compared separately. There was no statistically significant difference in the distribution with respect to healing, between the groups (P = .692). Conclusion: Although steroids––which are the only treatment with proven efficacy in sudden idiopathic hearing loss––are effective in the improvement of hearing, the methods of administration showed no differences in terms of effectiveness.
DergiAraştırma MakalesiErişime Açık
  • 1. Chandrasekhar SS, Tsai Do BS, Schwartz SR, et al. Clinical practice guideline: sudden hearing loss (update). Otolaryngol Head Neck Surg. 2019;161(1):S1-S45. [CrossRef]
  • 2. Sancaktar ME, Ağrı İ, Çeçen AB, Akgül G, Çelebi M. The prognostic value of circulating inflammatory cell counts in sudden sensorineural hearing loss and the effect of cardiovascular risk factors. Ear Nose Throat J. 2020;99(7):464-469. [CrossRef]
  • 3. Tezer MS, Baran Y, Erdur Ö, Ata N, Arslanhan M. Comparison of systemic, intratympanic and combination therapy of the steroids for the treatment of sudden sensorineural hearing loss Turkiye Klinikleri J Med Sci. 2013;33(2):353-359. [CrossRef]
  • 4. Ocak E, Beton S, Kesici GG, Akturk T. Can intratympanic steroid be initial therapy for sudden sensorineural hearing loss? Turk Arch Otolaryngol. 2014;52(1):12-16. [CrossRef]
  • 5. Wilson WR, Byl FM, Laird N. The efficacy of steroids in the treatment of idiopathic sudden hearing loss. A double blind clinical study. Arch Otolaryngol. 1980;106(12):772-776. [CrossRef]
  • 6. Moskowitz D, Lee KJ, Smith HW. Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope. 1984;94(5 Pt 1):664-666.
  • 7. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109(7 Pt 2):1-17. [CrossRef]
  • 8. Chandrasekhar SS. Intratympanic dexamethasone for sudden sensorineural hearing loss: clinical and laboratory evaluation. Otol Neurotol. 2001;22(1):18-23. [CrossRef]
  • 9. Ho HG, Lin HC, Shu MT, Yang CC, Tsai HT. Effectiveness of intratympanic dexamethasone injection in sudden-deafness patients as salvage treatment. Laryngoscope. 2004;114(7):1184-1189. [CrossRef])
  • 10. Toroslu T, Erdoğan H, Çağlar Ö, Güçlü O, Dereköy FS. Comparison of different treatment methods for idiopathic sudden sensorineural hearing loss. Turk Arch Otorhinolaryngol. 2018;56(4):226-232. [CrossRef]
  • 11. Tarkan Ö, Dağkıran M, Sürmelioğlu Ö, et al. Intratympanic methylprednisolone versus dexamethasone for the primary treatment of idiopathic sudden sensorineural hearing loss. J Int Adv Otol. 2018;14(3):451-455. [CrossRef]
  • 12. Müderris S, Öztürkcan S, Aykut M. Ani iflitme kay›plar›nda et- yoloji ve tedavi. KBB Postas. 1992;6:7-10.
  • 13. Hughes GB. Sudden hearing loss. In: Gates GA, ed. Current Therapy in Otolaryngology-Head and Neck Surgery. 6th ed. St. Louis: Mosby; 1998:41-44.
  • 14. Penido NO, Cruz OL, Zanoni A, Inoue DP. Classification and hearing evolution of patients with sudden sensorineural hearing loss. Braz J Med Biol Res. 2009;42(8):712-716. [CrossRef]
  • 15. Kopke RD, Hoffer ME, Wester D, O’Leary MJ, Jackson RL. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol. 2001;22(4):475-479. [CrossRef]
  • 16. Plontke SK, Löwenheim H, Mertens J, et al. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope. 2009;119(2):359-369. [CrossRef]
  • 17. She W, Dai Y, Du X, et al. Hearing evaluation of intratympanic methylprednisolone perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2010;142(2):266-271. [CrossRef]
  • 18. Labatut T, Daza MJ, Alonso A. Intratympanic steroids as primary initial treatment of idiopathic sudden sensorineural hearing loss. The Hospital Universitario Ramón y Cajal experience and review of the literature. Eur Arch Otorhinolaryngol. 2013;270(11):2823-2832. [CrossRef]
  • 19. Yang J, Huang L, Shi J, et al. The effect of intratympanic dexamethasone or methylprednisolone on treatment of sudden sensorineural hearing loss. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010;24(13):594-597.
  • 20. Berjis N, Soheilipour S, Musavi A, Hashemi SM. Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss. Adv Biomed Res. 2016;5:111. [CrossRef]
  • 21. Gianoli GJ, Li JC. Transtympanic steroids for treatment of sudden hearing loss. Otolaryngol Head Neck Surg. 2001;125(3):142-146. [CrossRef]
  • 22. Herr BD, Marzo SJ. Intratympanic steroid perfusion for refractory sudden sensorineural hearing loss. Otolaryngol Head Neck Surg. 2005;132(4):527-531. [CrossRef]
  • 23. Gümüşsoy M, Arslan İB, Çukurova İ. Comparative efficacies of intratympanic steroid administration and classic therapy in the management of idiopathic sudden sensorineural hearing loss. J Med Updates. 2013;3(2):51-55. [CrossRef]

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.